THE TRADEMA

PTO/SB/08A (08-03)
Approved for use through 07/31/2006, OMB 06S1-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Explection of information unless the section of information unless the section of th

Substitute for form 1449/PTO		risons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known				
				Application Number	10/810,517	
	INFORMATION DISCLOSURE			Filing Date	March 26, 2004	
STA	STATEMENT BY APPLICANT (Use as many sheets as necessary)		First Named Inventor	Kreft et al.		
	(USE AS N	iany sneets	s as necessary)	Group Art Unit	1626	
			Examiner Name	unassigned- 1626		
Sheet	1	of	6	Attorney Docket Number	AM-101251	

U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where			
Initials*	No.1	Number-Kind Code ^{2(U kmown)}	MM-DD-YYYY	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
GS	AA	US-5,981,168	P. Reiner	11-09-1999				
	AB	US-5,624,937	J. Reel	04-29-1997				
	AC	US-5,703,129	K. Felsenstein	12-30-1997				
	AD	US-5,593,846	D. Schenk	01-14-1997				
	AE	US-5,852,007	S. Chatterjee	12-22-1998				
·	AF	US-6,248,775	Vasquez	06-19-2001				
	AG	US-6,376,523	Chan, et al.	04-23-2002				
Ψ	AH	US-5,594,021	Chan, et al.	01-14-1997	Claims 1 and 2, and Specification			

FOREIGN PATENT DOCUMENTS								
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	70		
Initials*	No.1	Country Code3- Number4-Kind Code5(If known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures			
GS	AL	WO-95/29904-A1	11-09-1995	K. Chow	Appear	┼		
	AM	WO-98/03166-A1	01-29-1998	G. DeCrescenzo		-		
	AN	WO-98/22104-A3	05-28-1998	G. Pasinetti		╄		
	AO	WO-98/22493-A2	05-28-1998	J. Audia				
	AP	WO-00/09107-A2	02-24-2000	D. Ross		1		
V	AQ	WO-00/50391-A1	08-31-2000	D. Ross D. Smith		├_		

Examiner	7			
Signature	/Golam Shameem/	(09/14/2006)	Date	00/14/2000
# FWAMPHER -	<u> </u>		Considered	09/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is a stateched. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB contains. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a colle

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/810,517	
			DISCLOSURE	Filing Date	March 26, 2004	
			APPLICANT	First Named Inventor	Kreft et al.	
	(USE as II	iany sneet	as necessary)	Group Art Unit	1626	
				Examiner Name	unassigned	
Sheet	2	of	6	Attorney Docket Number	AM-101251	

U.S. PATENT DOCUMENTS							
Examiner Cite		Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where		
Initials*	No.1	Number-Kind Code ^{2(if known)}	MM-DD WW	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
LGS	AI	US-5,571,821	Chan, et al.	11-05-1996			
	AJ	US-5,464,853	Chan, et al.	01-07-1997			
1	AK	US-5,591,761	Chan, et al.	05-07-1996			
V	BA	US-5,514,691	Chan, et al.	11-07-1995			

•	FOREIGN PATENT DOCUMENTS									
F		<u></u>	Foreign Patent Document			Pages, Columns,	Т6			
Exam Initi	als*	ner Cite Publi		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures				
1	GS	BL	EP-652,009	05-10-1995	V. John	Appear	 			
		BM	EP-510,700-A2	10-28-1992	K. Itoh et al.	 	-			
┙		BN	EP-1,172,361-A1	12-14-1999	Watanabe et al.	 	┼			
		во	Љ-5-148233	06-15-1993	Y. Ito	 	1			
		BP	JP-11-343279	01-16-2002	F. Watanabe	 	 			
		BQ	WO-01/27091-A1	04-19-2001	Thompson		├			
		CL	WO-01/27108-A1	04-19-2001	Thompson	<u> </u>	├			
J		CM	WO-01/23379-A1	04-05-2001	Arkinstall et al.		₩			
V		CN	EP-1,088,821-A1	04-04-2001	Arkinstall		├			

Examiner			
	/Golam Shameem/ (09/14/2006)	Date	
Signature	/GOTAM DITAMEEM/ (03/14/2000)		09/14/2006
* EXAMINER : Initia	If reference considered whether as set should be	Considered	09/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for

PTO/SB/08A (08-03)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitut	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/810,517	
INFORMATION DISCLOSURE				Filing Date	March 26, 2004	
	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Kreft et al.	
	(USE as n	any sneet	s as necessary)	Group Art Unit	1626	
	·		Examiner Name	unassigned		
Sheet	3	of	6	Attorney Docket Number	AM-101251	

		THE PROPERTY OF THE PARTY OF TH	LITI 3	
Cite	Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where
No.1	Number-Kind Code ^{2(lfknown)}	MM-DD-YYYY	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
·BB	US-6,657,070	12-02-2003	Resnick, et	
			al.	
BC		08-26-2003	Kreft, et al.	
BD	US-20030229127-A1	12-11-2003		
BE	US-20030144531-A1	07-31-2003		
BF	US-20040006050-A1	01-08-2004		
BG	6,566,536	05-20-2003		
	BB BC BD BE BF	No.1 Number-Kind Code 2((I known)) BB US-6,657,070 BC US-6,610,734 BD US-20030229127-A1 BE US-20030144531-A1 BF US-20040006050-A1	Cite No.1 Document Number Publication Date MM-DD-YYYY BB US-6,657,070 12-02-2003 BC US-6,610,734 08-26-2003 BD US-20030229127-A1 12-11-2003 BE US-20030144531-A1 07-31-2003 BF US-20040006050-A1 01-08-2004	Number-Kind Code Number-Kind

FOREIGN PATENT DOCUMENTS									
		Foreign Patent Document			Pages, Columns,	т6			
Initials*	caminer Cite Publica	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures					
I GS	CO	WO-01/70677-A1	09-27-2001	Belanger et al.	Appear	\vdash			
	CP	WO-02/057252-A1	07-25-2002	Kreft et al.		┢			
	CQ	WO-03/050063-A1	06-19-2003	Kreft et al.		 			
	DL	WO-03/103660-A1	12-18-2003	Kreft et al.		├			
\mathbf{V}_{-}	DM	WO-03/050062-A1	06-19-2003	Resnick et al.	 				
	L					\vdash			

Evenie				
Examiner	/Golam Shameem/	(09/14/2006)	Date	00/14/0005
Signature	/ COTAIN DITAMEETH/	(0)/14/2000)	_ ` .	09/14/2006
* EVAMINED.	(-)41-4.16 . 6		Considered	1,,

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ¹See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to res

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
				Application Number	10/810,517
		Filing Date	March 26, 2004		
		APPLICANT	First Named Inventor	Kreft et al.	
		Group Art Unit	1626		
		Examiner Name	unassigned		
Sheet	4	of	6	Attorney Docket Number	AM-101251

<u> </u>	NONPATENT LITERATURE DOCUMENTS			
Examiner . Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²	
GS	AR	A. LARNER et al, "Review - Central & Peripheral Nervous Systems - Alzheimer's Disease: Towards Therapeutic Manipulation of the Amyloid Precursor Protein and Amyloid β-peptides", Exp. Opin. Ther. Patents, 7(10):1115-1127 (1997)		
	AS	C. MOORE et al, "Inhibition of β-amyloid Formation as a Therapeutic Strategy", Exp. Opin. Ther. Patents, 9(2):135-146 (1999)	-	
	AT	V. JOHN et al, "Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis", in Annual Reports in Medicinal Chemistry, Chapter 2, pp. 11-20 (1997)		
•	AU	G. RISHTON et al, "Fenchylamine Sulfonamide Inhibitors of Amyloid β Peptide Production by the γ-Secretase Proteolytic Pathway: Potential Small-Molecule Therapeutic Agents for the Treatment of Alzheimer's Disease", J. Med. Chem., 43(12):2297-2299 (June 15, 2000)		
	AV	B. TESTA et al, "Prodrugs Revisited: The "Ad Hoc" Approach as a Complement to Ligand Design", Medicinal Research Reviews, 16(3):233-241 (May, 1996)		
	AW	D. SKOVRONSKY et al, "β-Secretase Revealed: Starting Gate for Race to Novel Therapies for Alzheimer's Disease", TIPS, 21:161-163 (May, 2000)	-	
	AX	A. GHOSH et al, "Design of Potent Inhibitors for Human Brain Memapsin 2 (β-Secretase)", J. Am. Chem. Soc., 122:3522-3523 (2000)	_	
	AY	W. ESLER et al, "Transition-State Analogue Inhibitors of γ-Secretase Bind Directly to Presenilin-1", Nature Cell Biology, 2:428-434 (July, 2000)		
	AZ	Y-M. LI et al, "Photoactivated γ-Secretase Inhibitors Directed to the Active Site Covalently Label Presenilin 1", Nature, 405:689-694 (June, 2000)		
V	BR	M. WOLFE et al, "A Substrate-Based Difluoro Ketone Selectively Inhibits Alzheimer's β-Secretase Activity", J. Med. Chem., 41:6-9 (January 1, 1998)		

Examiner			
Signature	/Golam Shameem/ (09/14/2006)	Date	09/14/2006
	7 30 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Considered	1 03, 22, 2000

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not ¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional).

² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/312/006. OMB 0551-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMENCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

6

Sheet

	Complete if Known	
Application Number	10/810,517	
Filing Date	March 26, 2004	_
First Named Inventor	Kreft et al.	_
Group Art Unit	1626	
Examiner Name	unassigned	_
Attorney Docket Number	AM-101251	_

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	of T ²	
GS 	BS	S. SINHA et al, "Purification and Cloning of Amyloid Precursor Protein β-Secretase from Human Brain", Nature, 402:537-540 (December, 1999)		
	ВТ	A. GOATE, "Monogenetic Determinants of Alzheimer's Disease: APP Mutations", CMLS Cell. Mol. Life Sci., 54:897-901 (September, 1998)		
	BU	M. SABBAGH et al, "β-Amyloid and Treatment Opportunities for Alzheimer's Disease", Alzheimer's Disease Review, 3:1-19 (1997)		
•	BV	C. AUGELLI-SZAFRAN et al, "β-Amyloid as a Target for Alzheimer's Disease Therapy, in Annual Reports in Medicinal Chemistry, Chapter 3, pp. 21-30 (1990)	-	
•	BW	Biology to Learning and Memory Processes", Reviews in the Neurosciences, 11(2-3):75-93 (2000)		
	BX	D. SMALL et al, "Alzheimer's Disease and the Amyloid β Protein: What is the Role of Amyloid?", Journal of Neurochemistry, 73(2):443-449 (August, 1999)		
	BY	J. NASLUND et al, "Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline", JAMA, 283(12):1571-1577 (March, 2000)		
	BZ	Q-X. LI et al, "The Amyloid Precursor Protein of Alzheimer Disease in Human Brain and Blood", Journal of Leukocyte Biology, 66:567-574 (October, 1999)		
	CR	S. WAGNER et al, "Modulation of Amyloid β Protein Precursor Processing as a Means of Retarding Progression of Alzheimer's Disease", The Journal of Clinical Investigation, 104(10):1329-1332 (November, 1999)		
	CS	Y. HAN et al, "Total Asymmetric Synthesis of Highly Constrained Amino Acids Isopropyl-2', 6'-Dimethyl-Tyrosines". Tetrahedron Letters, 38(20):5135-5138 (1007)		
V	СТ	M. FINDEIS et al, "Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization", Biochemistry, 38(21):6791-6800 (May, 1999)		

P			
Examiner			
o .	/Golam Shameem/ (09/14/2006)	Date	
Signature		1	1
		Considered	09/14/2006
		Colbidated	1 05/14/2000

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to Complete if Known Substitute for form 1449/PTO **Application Number** 10/810.517 **INFORMATION DISCLOSURE** Filing Date March 26, 2004 STATEMENT BY APPLICANT First Named Inventor Kreft et al. Group Art Unit 1626 (Use as many sheets as necessary) **Examiner Name** unassigned Sheet 6 of 6 Attorney Docket Number AM-101251

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GS	CU ROGGO, "Inhibition of BACE, A Promising Approach to Alzheimer's Disease Therapy", Curr. Top. Med. Chem., 2(4): 359-70 (April 2002)		
	CV	TUNG et al., "Design of Substrate-Based Inhibitors of Human β-Secretase", J. Med. Chem., 45(2):259-262 (2002)	
	CW	JOSIEN, "Recent Advances in the Development of Gamma-Secretase Inhibitors", Curr. Opin. Drug. Discov. Devel., 5(4):513-25 (July 2002)	
-	СХ	DOVEY et al., "Functional Gamma-Secretase Inhibitors Reduce Beta-Amyloid Peptide Levels in Brain", J. Neurochem. 76:173-181 (January 2001)	
•	CY	OLSON et al., "Chapter 4. Secretase Inhibitors as Therapeutics for Alzheimer's Disease", Ann. Reports in Med. Chem. 35:31 (2000)	
	CZ	VARGHESE et al., "Chapter 2. Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis", Ann. Reports Med. Chem., 32:11 (1997)	
V	DL	Abstract of Japanese Patent No. JP-11-343279, January 26, 2002	
		·	

Signature / GOTam Snameem/ (09/14/2006) Date 09/14/2006				
Signature / GOTam Shameem/ (09/14/2006) Date 09/14/2006	Examiner	(Co) 2m Chamaom / /09/14/2006		
[Ogistate] 1 09/14/2006	Signature	/GOTam Shameem/ (03/14/2006)	Date	
	Orgitature			1 09/14/2006 1
Considered 07/14/2000			Considered	1 05/14/2000

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Reperwork Reduction Act of 1995, no persons at Substitute for form 1996	e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitute for form 14404-70	Application Number	10/810,517	
INFORMATION DISCLOSURE	Filing Date	March 26, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Kreft et al.	
	Art Unit	1626	
(Use as many sheets as necessary)	Examiner Name	u nassigned- 1626	
Sheet 1 of 1	Attorney Docket Number	AM-101251	

	NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of th		T ²			
GS	DM	WERMUTH et al., "Molecular variations based on isosteric replacements", Prac. Med. Chem., Academic Press, pp. 203-237 (February 1996)			
		-			
-					
_					

Examiner	/Golam Shameem/ (09/14	(2006) Date	09/14/2006
Signature	/ 001am Diamodm/ (05/11	Considered	03/14/2000

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.